EP300 association with gastroesophageal cancer survival: a meta-analysis

Qi Wang^#, Zhi Cui^#, Mu-hong Deng^#, Quan-li Han^#,*

Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, China

Introduction: Gastroesophageal cancer (GSC) is heavy burden world-wide. In recent decade, lots of genetic/proteomic studies among cancer susceptibility and prognosis has been established. One of the proteins called P300 has been well studied. This meta-analysis was trying to confirm if EP300 could have impact on 5-year overall survival. 

Materials and methods: Medline and web of knowledge, using the following search terms: ‘‘oesophageal’’ or ‘‘esophageal’’ or “Laryngeal carcinoma” or “Gastric cancer” or “gastroesophageal” and ‘‘EP300’’ or ‘‘P300’’ or “KATB” and “cancer” or “carcinoma” and “survival” or “outcome” or “response rate” . After reviewing, we collected research data from 8 studies, including 1351 GSC cases.

Results: In this study, we collected 8 studies with a total of 1,361 cases of GSC subjects. The results showed that P300 positive is overall associated with 5-year survival (OR: 3.01 [95% CI, 2.32-3.90], P<0.001), in subgroup analysis, esophageal cancer subgroup showed no heterogeneity and significantly result in P300 positive and with 5-year survival (OR=3.16, 95%CI [2.14-4.67], P<0.001). However, other cancer type patients showed a high heterogeneity. 

Conclusion: In this analysis, we found that P300 positive might be a good biomarker for esophageal cancer 5-year overall survival.